Data source: Benchling · liveNeogene Stevenage · GxP
v0.1 prototype
MO
Back to cockpitfrom Benchling
Lot
NGN-2026-0143
TCR-T (NY-ESO-1) · Synovial sarcoma · Rockville (US) · patient PT-8847
AI RELEASE RECOMMENDATION
Decision support for NGN-2026-0143
Synthesizes every Benchling-ingested acceptance criterion into a single verdict with reasoning. The reviewer signs off in Benchling.
Acceptance criteria
Live results streamed from Benchling-connected instruments.
| Criterion | Spec | Observed | Instrument | Status |
|---|---|---|---|---|
| Viability Cell count & viability | ≥ 70% | — | NucleoCounter NC-200 #01analysis → | pending |
| %CD3+ T cells Identity (flow) | ≥ 80% | — | BD FACSLyric #01analysis → | pending |
| %CAR+ transduction Identity (flow) | 20–60% | — | BD FACSLyric #01analysis → | pending |
| Vector copy number Safety (qPCR) | ≤ 5 copies/cell | 2.8 | QuantStudio 7 Flex | pass |
| Endotoxin Safety (LAL) | < 0.5 EU/mL | 0.12 EU/mL | EndoSafe nexgen-PTS | pass |
| Sterility (14-day) Safety (microbial) | No growth | day 4/14 | BacT/ALERT 3D | pending |
| Mycoplasma Safety (qPCR) | Negative | Negative | QuantStudio 7 Flex | pass |
| Potency (cytolysis @ E:T 10:1) Potency | ≥ 40% | — | xCELLigence RTCAanalysis → | pending |